• Corpus ID: 18777869

Competition driven cancer immunoediting

  title={Competition driven cancer immunoediting},
  author={Irina Kareva},
  journal={arXiv: Tissues and Organs},
  • I. Kareva
  • Published 29 July 2014
  • Biology
  • arXiv: Tissues and Organs
It is a well-established fact that tumors up-regulate glucose consumption to meet increasing demands for rapidly available energy by switching to purely glycolytic mode of glucose metabolism. What is often neglected is that cytotoxic cells of the immune system also have increased energy demands and also switch to pure glycolysis when they are in an activated state. Moreover, while cancer cells can revert back to aerobic metabolism, rapidly proliferating cytotoxic lymphocytes are incapable of… 

Figures and Tables from this paper

Immune evasion through competitive inhibition: the shielding effect of cancer non-stem cells.
  • I. Kareva
  • Biology
    Journal of theoretical biology
  • 2015


Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond.
Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival
Understanding of the signals that regulate the expression and localization of glucose transporter 1 (Glut1) to allow glucose uptake in T cells are beginning to be understood and may lead to therapeutic strategies to target some forms of cancer or autoimmunity.
Why do cancers have high aerobic glycolysis?
It is proposed that persistent metabolism of glucose to lactate even in aerobic conditions is an adaptation to intermittent hypoxia in pre-malignant lesions, which leads to microenvironmental acidosis requiring evolution to phenotypes resistant to acid-induced cell toxicity.
Fuel feeds function: energy metabolism and the T-cell response
This Review describes how T cells actively acquire metabolic substrates from their environment to meet these energy demands and respond appropriately to pathogens.
Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells.
  • O. Feron
  • Biology
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • 2009
Improved Endpoints for Cancer Immunotherapy Trials
A body of clinical and laboratory data was generated that supports three novel endpoint recommendations that may improve tools for cancer immunotherapy trials and may offer a more realistic and useful model for clinical investigation.
Activation of apoptosis pathways in peripheral blood lymphocytes by in vivo chemotherapy.
Induction of apoptosis regulators was analyzed in peripheral blood lymphocytes from pediatric patients undergoing first-cycle chemotherapy for solid tumors to suggest that chemotherapy-induced lymphocyte depletion involves distinct mechanisms of apoptotic induction, such as direct mitochondrial and caspase- dependent pathways in resting cells and p53-dependent pathways in cycling lymphocytes.
Lymphocyte depletion during treatment with intensive chemotherapy for cancer.
Based on the history of opportunistic complications in patients with other disorders who display similar degrees of CD4+ T-cell lymphopenia and preliminary observations in this population, immune incompetence could surface as a dose-limiting toxicity for highly dose-intensive chemotherapy regimens.
Cancer immunotherapy – revisited
The recent positive results of clinical trials with novel immunoactive drugs as well as the unexpected finding of a positive interaction between immunotherapy and chemotherapy may herald a new era for the immunotherapy of cancer.